stockrow
Wednesday 4 November 2026
Export ALT’s income statement to Excel — free account
Altimmune, Inc.
Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024.
- Revenue
- +520.0%
- EPS
- +55.6%
- Free cash flow
- −25.3%
- Total debt
- +142.4%
Quarter to June 2026, against a year earlier
2.10
0.06
+2.94%
Follow ALT
Alert me
Altimmune, Inc. (ALT) P/E ratio
Altimmune, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 2.8× (December 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 40 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.8×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | n/m |
| AVTX Avalo Therapeutics, Inc. compare | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| ALT Altimmune, Inc. | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.6× |
| Market median | 18.3× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)